| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1049472065 |
| P356 | DOI | 10.1007/S11060-016-2075-3 |
| P698 | PubMed publication ID | 26909695 |
| P50 | author | Shivam Om Mittal | Q59004258 |
| Rezvan Rostami | Q95946338 | ||
| P2093 | author name string | Bahman Jabbari | |
| Fattaneh Tavassoli | |||
| Pooya Rostami | |||
| P2860 | cites work | Genes that mediate breast cancer metastasis to the brain | Q24644008 |
| Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients | Q33300250 | ||
| Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. | Q45773281 | ||
| Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer | Q46116627 | ||
| Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome | Q46782051 | ||
| Distant metastasis in triple-negative breast cancer | Q46824953 | ||
| Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian | Q47793228 | ||
| Capecitabine therapy of central nervous system metastases from breast cancer | Q48115520 | ||
| Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer | Q48142933 | ||
| The factors that have an impact on the development of brain metastasis in the patients with breast cancer | Q48188705 | ||
| Breast cancer subtypes predispose the site of distant metastases | Q48276930 | ||
| Radiosurgery with 20 Gy provides better local contol of 1-3 brain metastases from breast cancer than with lower doses. | Q48394432 | ||
| Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis | Q48404872 | ||
| Surgical treatment of 70 patients with brain metastases from breast carcinoma | Q48598959 | ||
| Treatment and outcome of brain metastasis as first site of distant metastasis from breast cancer | Q48611620 | ||
| Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis | Q48614511 | ||
| Distinct MR Imaging Features of Triple-Negative Breast Cancer with Brain Metastasis | Q48638578 | ||
| Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea. | Q54594367 | ||
| Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer | Q58849543 | ||
| Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers | Q60547879 | ||
| Breast cancer: metastatic patterns and their prognosis | Q68514094 | ||
| Treatment and prognosis of brain metastases from breast cancer | Q81235660 | ||
| Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy | Q81242220 | ||
| Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis | Q81500082 | ||
| Prognostic factors in patients with metastatic breast cancer at the time of diagnosis | Q87455376 | ||
| Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer | Q33511035 | ||
| Identification of breast cancer patients with a high risk of developing brain metastases: a single-institutional retrospective analysis. | Q33553971 | ||
| Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. | Q33829773 | ||
| Deconstructing the molecular portraits of breast cancer | Q34154147 | ||
| Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. | Q34192343 | ||
| Systemic treatment after whole-brain radiotherapy may improve survival in RPA class II/III breast cancer patients with brain metastasis | Q34762284 | ||
| Emerging strategies for treating brain metastases from breast cancer | Q35075446 | ||
| Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients | Q35107204 | ||
| Brain metastasis from ovarian cancer: a systematic review | Q35161900 | ||
| Local control of brain metastasis: treatment outcome of focal brain treatments in relation to subtypes. | Q35237206 | ||
| Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis | Q35586669 | ||
| Predictors for long-term survival free from whole brain radiation therapy in patients treated with radiosurgery for limited brain metastases | Q35591189 | ||
| Outcomes and predictors of improved survival after gamma knife radiosurgery for metastatic brain tumors originated from breast carcinoma | Q35595355 | ||
| The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain | Q35687321 | ||
| Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors | Q35808400 | ||
| CNS metastases in breast cancer | Q35874807 | ||
| Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy | Q35928878 | ||
| Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. | Q36107363 | ||
| Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial | Q36284456 | ||
| Incidence and risk factors for leptomeningeal carcinomatosis in breast cancer patients with parenchymal brain metastases | Q36354078 | ||
| Primary extraosseous Ewing sarcoma of the lung in children | Q36791086 | ||
| Breast cancer brain metastases: new directions in systemic therapy | Q36822500 | ||
| Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab | Q36862845 | ||
| Survival following gamma knife radiosurgery for brain metastasis from breast cancer | Q36972484 | ||
| Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization | Q37185154 | ||
| Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer | Q37716408 | ||
| Factors associated with mortality after breast cancer metastasis | Q40004897 | ||
| Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer | Q42463524 | ||
| Site preference of metastatic tumours of the brain | Q42512750 | ||
| Brain metastases in breast cancer; natural history, prognostic factors and outcome | Q43411645 | ||
| Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study | Q43522608 | ||
| Breast cancer subtypes and outcomes of central nervous system metastases. | Q43966702 | ||
| Incidence of and survival following brain metastases among women with inflammatory breast cancer | Q44136747 | ||
| The natural history of breast cancer patients with brain metastases | Q44250463 | ||
| The proinflammatory peptide substance P promotes blood-brain barrier breaching by breast cancer cells through changes in microvascular endothelial cell tight junctions | Q44587816 | ||
| The number of involved extracranial organs: a new predictor of survival in breast cancer patients with brain metastasis | Q44616500 | ||
| Efficiency and prognosis of whole brain irradiation combined with precise radiotherapy on triple-negative breast cancer | Q45006943 | ||
| The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival | Q45757920 | ||
| P433 | issue | 3 | |
| P921 | main subject | breast cancer | Q128581 |
| brain metastasis | Q1620196 | ||
| literature review | Q2412849 | ||
| P304 | page(s) | 407-414 | |
| P577 | publication date | 2016-02-24 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Brain metastasis in breast cancer: a comprehensive literature review | |
| P478 | volume | 127 |
| Q40953860 | A Case of Breast Cancer Brain Metastasis with a 16-Year Time Interval without Evidence of Cancer Recurrence |
| Q47239487 | Arachidonic Acid Metabolite as a Novel Therapeutic Target in Breast Cancer Metastasis |
| Q57176317 | Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine |
| Q64228202 | Brain metastases from breast cancer may respond to endocrine therapy: report of two cases |
| Q90655998 | Brain metastasis-related microRNAs in patients with advanced breast cancer |
| Q55308550 | Breast Cancer-Derived Exosomes Alter Macrophage Polarization via gp130/STAT3 Signaling. |
| Q36253544 | Breast carcinoma subtypes show different patterns of metastatic behavior |
| Q58087849 | Clinical application of quantitative glycomics |
| Q92191742 | Clinical characteristics of CNS metastases from primary gynecologic cancers |
| Q37515347 | Clinical features of brain metastases in breast cancer: an implication for hippocampal-sparing whole-brain radiation therapy |
| Q40977689 | Clinical outcome of brain metastases differs significantly among breast cancer subtypes |
| Q90128600 | Clinical outcome of patients with brain metastases from breast cancer - A population based study over 21 years |
| Q38702952 | Comparative membrane proteomics analyses of breast cancer cell lines to understand the molecular mechanism of breast cancer brain metastasis |
| Q47162071 | Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer |
| Q38611108 | Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis |
| Q60926921 | Comparisons of metastatic patterns of colorectal cancer among patients by age group: a population-based study |
| Q47098306 | Comprehensive molecular biomarker identification in breast cancer brain metastases |
| Q87742397 | Cucurbitacin B suppresses metastasis mediated by reactive oxygen species (ROS) via focal adhesion kinase (FAK) in breast cancer MDA-MB-231 cells |
| Q52578959 | Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. |
| Q38369233 | Deep sequencing reveals the mitochondrial DNA variation landscapes of breast-to-brain metastasis blood samples |
| Q47629685 | Effects of FSTL1 on cell proliferation in breast cancer cell line MDA‑MB‑231 and its brain metastatic variant MDA‑MB‑231‑BR. |
| Q47839509 | Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review |
| Q38752195 | Estimating the annual frequency of synchronous brain metastasis in the United States 2010-2013: a population-based study. |
| Q98210304 | Evaluation of imaging findings and prognostic factors after whole-brain radiotherapy for carcinomatous meningitis from breast cancer: A retrospective analysis |
| Q48108646 | Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases |
| Q92401376 | Gamma Knife Radiosurgery for the Management of More Than 15 Cerebral Metastases |
| Q99635794 | Genomic landscape of the immune microenvironments of brain metastases in breast cancer |
| Q90008303 | Identification of ALDH1A3 as a viable therapeutic target in breast cancer metastasis-initiating cells |
| Q95843521 | Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms |
| Q90410649 | Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases |
| Q91405244 | Integrated Transcriptomics, Proteomics, and Glycomics Reveals the Association between Up-regulation of Sialylated N-glycans/Integrin and Breast Cancer Brain Metastasis |
| Q54118354 | Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. |
| Q57167169 | Low-Intensity MR-Guided Focused Ultrasound Mediated Disruption of the Blood-Brain Barrier for Intracranial Metastatic Diseases |
| Q54940766 | Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer. |
| Q97652827 | Nephronectin promotes breast cancer brain metastatic colonization via its integrin-binding domains |
| Q89113047 | Neurosurgical management of brain metastases |
| Q57175453 | Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer |
| Q90376945 | Operative and peri-operative considerations in the management of brain metastasis |
| Q90291603 | Outcome of Omani Women with Breast Cancer-associated Brain Metastases Experience from a University Hospital |
| Q91976219 | PTHrP, A Biomarker for CNS Metastasis in Triple-Negative Breast Cancer and Selection for Adjuvant Chemotherapy in Node-Negative Disease |
| Q64279228 | Paracellular and transcellular migration of metastatic cells through the cerebral endothelium |
| Q90429903 | Parathyroid Hormone-Related Protein (PTHrP): An Emerging Target in Cancer Progression and Metastasis |
| Q89210731 | Posterior Fossa Metastasis-Associated Obstructive Hydrocephalus in Adult Patients: Literature Review and Practical Considerations from the Neuro-Oncology Club of the French Society of Neurosurgery |
| Q89161805 | Profiles of brain metastases: Prioritization of therapeutic targets |
| Q91608266 | Prognostic Value of Brain Metastasis-Free Interval in Patients with Breast Cancer Brain Metastases |
| Q89940647 | Risk factors for breast cancer brain metastases: a systematic review |
| Q64060765 | Successful treatment of brain radiation necrosis resulting from triple-negative breast cancer with Endostar and short-term hyperbaric oxygen therapy: a case report |
| Q45072965 | Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer |
| Q103723872 | Treatment strategies for breast cancer brain metastases |
| Q44152087 | Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer |
Search more.